AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16698007
Drug: Aspirin 200
RxNorm normalized name: aspirin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 200 mg/day
Trial: 16698007
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 1 g/day
Trial: 10781643
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 400 mg/day
Trial: 8225684
Drug: Voltaren (V)
RxNorm normalized name: Voltarene
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Voltaren (V) 100 mg tablet
Trial: 8225684
Drug: Diclogesic (D)
RxNorm normalized name: Dologesic
DrugBank: Phenyltoloxamine (DB11160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diclogesic (D) 100 mg tablet
Trial: 7622644
Drug: Astemizole 10
RxNorm normalized name: astemizole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole 10 mg
Trial: 21082306
Drug: Invisalign treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invisalign treatment
Trial: 29384762
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (traditional rehabilitative treatment)
Trial: 27356528
Drug: High-sodium and
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sodium and bicarbonate mineral water (BW, sodium 1 g/L; bicarbonate 2 g/L)
Trial: 23140347
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy (112 patients, 22.5% of total)
Trial: 23140347
Drug: Non-ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ICD therapy (385 patients)
Trial: 12358251
Drug: Tegaserod 2
RxNorm normalized name: tegaserod 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod 2 or 6 mg b.i.d. (n = 1679)
Trial: 12358251
Drug: Tegaserod iv.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod iv. single doses (0.8 mg to 20 mg)
Trial: 1664903
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) subfraction, initial dose of 17 to 95 U/kg and continuous dose of 7 to 20 U/kg/hr
Trial: 7247733
Drug: Fenofibrate 300mg
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate 300mg daily for 1 year
Trial: 26359512
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg (high-dose statin therapy)
Trial: 26359512
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg (low-dose statin therapy)
Trial: 17409969
Drug: Gefitinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (250 mg/day)
Trial: 14739683
Drug: Agalsidase alfa
RxNorm normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Agalsidase alfa enzyme replacement therapy
Trial: 8839837
Drug: Low-dose sIL-1RI
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sIL-1RI
Trial: 8839837
Drug: High-dose sIL-1RI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sIL-1RI
Trial: 8839837
Drug: sIL-1RI (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sIL-1RI (both doses)
Trial: 6385681
Drug: Diltiazem, 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem, 360 mg/day
Trial: 29551030
Drug: Eltrombopag (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag (25 mg/d)
Trial: 23857041
Drug: Automatic titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automatic titration guided by the BIS (dual-loop group)
Trial: 23857041
Drug: Manual target-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual target-controlled infusion of propofol and remifentanil (manual TCI group)
Trial: 20956635
Drug: Fixed starting
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed starting dose
Trial: 17026488
Drug: RSG/MET fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSG/MET fixed-dose combination therapy (AVANDAMET) 4 mg/1000 mg up-titrated to 8 mg/2000 mg
Trial: 17026488
Drug: RSG/MET fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSG/MET fixed-dose combination therapy (AVANDAMET)
Trial: 10722500
Drug: Amprenavir, 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amprenavir, 1,200 mg twice daily over 4 days (seven doses)
Trial: 10722500
Drug: Clarithromycin, 500
RxNorm normalized name: Clarithromycin, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin, 500 mg twice daily over 4 days (seven doses)
Trial: 10722500
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of amprenavir and clarithromycin over 4 days (seven doses of each drug)
Trial: 1444526
Drug: 0.3 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g/kg IVIG at two week intervals
Trial: 3932106
Drug: Dexchlorpheniramine maleate
RxNorm normalized name: Dexchlorpheniramine Maleate
DrugBank: Dexchlorpheniramine (DB13679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexchlorpheniramine maleate 6 mg b.i.d.
Trial: 25139882
Drug: Glucagon 25
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon 25 μg
Trial: 25139882
Drug: Glucagon 75
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon 75 μg
Trial: 25139882
Drug: Glucagon 125
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon 125 μg
Trial: 25139882
Drug: Glucagon 175
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon 175 μg
Trial: 25139882
Drug: High insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High insulin levels (0.05 units/kg/h)
Trial: 20706110
Drug: Intermittent CPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent CPT (thrice weekly)
Trial: 20706110
Drug: Daily CPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily CPT
Trial: 16798862
Drug: Atraumatic Restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic Restorative Treatment (ART) with high-viscosity glass ionomer
Trial: 10974963
Drug: Active medication
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active medication review by a pharmacist
Trial: 1323576
Drug: 10(6) TCID50
RxNorm normalized name: adenovirus type 4 vaccine live
DrugBank: Human adenovirus e serotype 4 strain cl-68578 antigen (DB14409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10(6) TCID50 of CP18 PIV‐3 vaccine administered intranasally to seropositive older children (41 to 124 months)
Trial: 1323576
Drug: 10(5) TCID50
RxNorm normalized name: adenovirus type 4 vaccine live
DrugBank: Human adenovirus e serotype 4 strain cl-68578 antigen (DB14409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10(5) TCID50 of CP18 PIV‐3 vaccine administered intranasally to seropositive young children
Trial: 1323576
Drug: 10(6) TCID50
RxNorm normalized name: adenovirus type 4 vaccine live
DrugBank: Human adenovirus e serotype 4 strain cl-68578 antigen (DB14409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10(6) TCID50 of CP18 PIV‐3 vaccine administered intranasally to seropositive young children
Trial: 1323576
Drug: 10(6) TCID50
RxNorm normalized name: adenovirus type 4 vaccine live
DrugBank: Human adenovirus e serotype 4 strain cl-68578 antigen (DB14409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10(6) TCID50 of CP18 PIV‐3 vaccine administered intranasally to seronegative young children
Trial: 1323576
Drug: CP18 PIV‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP18 PIV‐3 vaccine in seronegative young children
Trial: 1323576
Drug: Vaccine virus
RxNorm normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine virus spread from a vaccinated child to a sibling control
Trial: 31168922
Drug: Intensive lifestyle
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive lifestyle intervention (5-6 weekly aerobic and combined aerobic and strength training sessions, 30-60 minutes, individual dietary plans aiming for BMI ≤25 kg/m2)
Trial: 31168922
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (standardized, blinded, target-driven medical therapy during the initial 12 months)
Trial: 30170399
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine fumigation 'Bone-healing Powder'
Trial: 27210235
Drug: BoNT/A injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT/A injection (100 units)
Trial: 25219601
Drug: Baicalein (100-2800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baicalein (100-2800 mg)
Trial: 22727067
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of nateglinide (60 mg)
Trial: 22727067
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of nateglinide (60 mg)
Trial: 19655157
Drug: Ethinylestradiol +
RxNorm normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinylestradiol + cyproterone acetate (2 mg, EE/CA)
Trial: 19655157
Drug: Ethinylestradiol +
RxNorm normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinylestradiol + cyproterone acetate (2 mg, EE/CA) with spironolactone (Sp)
Trial: 17585086
Drug: Hydrocortisone (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (1200 mg/d for 10 days, tapered thereafter)
Trial: 10549990
Drug: GHB (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB (50 mg/kg body weight for 10 days)
Trial: 10549990
Drug: Diazepam (0.5-0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.5-0.75 mg/kg body weight for 6 days, tapering the dose 25% daily until day 10)
Trial: 7634674
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for avulsion fractures (no immobilization)
Trial: 7634674
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for shaft/neck fractures (plaster casts with weight bearing as tolerated)
Trial: 7634674
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for true Jones' fractures (8 weeks nonweight bearing followed by weight bearing as tolerated in a cast)
Trial: 7634674
Drug: Surgical fixation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical fixation for conservative treatment failure
Trial: 2179764
Drug: 5 X
RxNorm normalized name: PAD,ABDOMINAL 5 X 9 STERILE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 X 10(6) IU IFN subcutaneously daily for 6 months
Trial: 30972062
Drug: Myeloid-derived cells
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myeloid-derived cells targeted treatments
Trial: 21261786
Drug: Oral and/or
RxNorm normalized name: Chloral and/or chloral derivative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and/or parenteral rehydration solutions
Trial: 19479626
Drug: Quercetin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (250 mg)
Trial: 15319599
Drug: 99mTc nanocolloid
RxNorm normalized name: 99mTc medronate
DrugBank: Technetium Tc-99m medronate (DB09138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc nanocolloid (99mTc‐NC) (10 MBq) and 111In‐HIG (2 MBq) as a mixture (0.2 ml)
Trial: 15319599
Drug: 99mTc‐HIG (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc‐HIG (10 MBq) and 111In‐HIG (2 MBq) as a mixture (0.2 ml)
Trial: 15319599
Drug: 99mTc‐HIG (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc‐HIG (10 MBq) and 111In‐HIG (2 MBq) separately (both 0.2 ml)
Trial: 9611088
Drug: Tryptophan depletion
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tryptophan depletion (TD) challenge with 43 g of an amino acid mixture containing five large neutral amino acids
Trial: 9611088
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received the same amino acid mixture with 2.3 g tryptophan added
Trial: 9611088
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of platelet serotonin-receptor function and plasma prolactin levels
Trial: 30999382
Drug: Combined massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined massage therapy and phototherapy
Trial: 28343774
Drug: 60μg recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60μg recombinant hepatitis B vaccine
Trial: 28343774
Drug: 20μg recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20μg recombinant hepatitis B vaccine
Trial: 28343774
Drug: Both 20μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both 20μg and 60μg vaccine groups
Trial: 26521577
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation therapy (intermittent catheterization and bladder function training)
Trial: 22083887
Drug: Routine 3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine 3,000 mL LCAP
Trial: 15073160
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) at a dosage of 300-500 mg/kg (most commonly 400 mg/kg)
Trial: 11319684
Drug: HPV-11 L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-11 L1 VLP vaccine
Trial: 2446080
Drug: Intravenous ketanserin
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketanserin (0.15 mg/kg)
Trial: 27466602
Drug: Soy-dairy protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy-dairy protein blend (PB) supplementation (22 g daily)
Trial: 27466602
Drug: Combined PB
RxNorm normalized name: PB-722
DrugBank: PB-722 (DB18447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined PB and WP treatments
Trial: 28346813
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (PB, WP, MDP)
Trial: 18547727
Drug: Escitalopram 20mg
RxNorm normalized name: Escitalopram 20mg Oral tablet
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram 20mg once daily
Trial: 15647413
Drug: Hibiscus sabdariffa
RxNorm normalized name: HIBISCUS SABDARIFFA CALYX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hibiscus sabdariffa L. extract (150 mL yielding 62.6 mg of cyanidin‐3‐sambubioside, 81.6 mg of delphinidin‐3‐sambubioside, and 147.4 mg of total anthocyanins)
Trial: 15647413
Drug: Hibiscus sabdariffa
RxNorm normalized name: HIBISCUS SABDARIFFA CALYX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hibiscus sabdariffa L. extract
Trial: 10862852
Drug: Prostaglandin E(2)
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E(2) gel (0.5 microg every 6 hours for two doses followed by oxytocin if indicated)
Trial: 9932568
Drug: Extra-amniotic saline
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-amniotic saline infusion
Trial: 9089422
Drug: AZT-P-ddI (IVX-E-59)
RxNorm normalized name: E.P.O.
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZT-P-ddI (IVX-E-59) intravenous administration (50 mg and 100 mg)
Trial: 9089422
Drug: AZT-P-ddI (IVX-E-59)
RxNorm normalized name: E.P.O.
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZT-P-ddI (IVX-E-59) oral administration (100 mg and 200 mg)
Trial: 9089422
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg oral dose of AZT-P-ddI
Trial: 9089422
Drug: AZT-P-ddI (IVX-E-59)
RxNorm normalized name: E.P.O.
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZT-P-ddI (IVX-E-59) oral administration
Trial: 9089422
Drug: AZT-P-ddI (IVX-E-59)
RxNorm normalized name: E.P.O.
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZT-P-ddI (IVX-E-59) oral and intravenous administration
Trial: 8478959
Drug: 0.5 g/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/m2 DFMO every day (step 3)
Trial: 8478959
Drug: 0.125, 0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125, 0.25, 0.5, or 0.75 g/m2 DFMO four times a day (step 1)
Trial: 8478959
Drug: 0.125 or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 or 0.25 g/m2 four times a day or 0.5 or 1.0 g/m2 every day (step 2)
Trial: 8478959
Drug: 0.5 g/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/m2 DFMO every day
Trial: 27128958
Drug: Minocycline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (50 mg twice per day)
Trial: 24452704
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A injection at the proximal 2/10 and 3/10 of calf length
Trial: 24452704
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A injection at and below the midbelly of the muscle (Control)
Trial: 22157067
Drug: MRI-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI-guided treatment decision (group 2)
Trial: 22157067
Drug: MRI-blinded treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI-blinded treatment decision (group 1)
Trial: 22157067
Drug: Different injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different injection than proposed by independent physician (group 1)
Trial: 22157067
Drug: Injection correlated
RxNorm normalized name: TUBING,CORRUGATED FLEX HUDSON #1680
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection correlated with imaging (group 1)
Trial: 16183781
Drug: Propiverine 15
RxNorm normalized name: propiverine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine 15 mg twice daily for 7 days
Trial: 11291023
Drug: Psychopharmacologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychopharmacologic treatment for hypersexuality
Trial: 11291023
Drug: Clinical algorithm
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical algorithm for treatment
Trial: 31711417
Drug: Ephedrine 20
RxNorm normalized name: DM 10/PSEUDOEPHEDRINE 20MG/5ML LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 20 mg (E group)
Trial: 31711417
Drug: Phenylephrine 250
RxNorm normalized name: acetaminophen-phenylephrine 250 mg-5 mg oral tablet, effervescent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine 250 mcg (P group)
Trial: 16648333
Drug: Video-feedback interactional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video-feedback interactional treatment
Trial: 10926346
Drug: Salmeterol/fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone propionate combination product (SFC) 50/250 microg twice daily
Trial: 1526015
Drug: UK 79300
RxNorm normalized name: UK-390957
DrugBank: UK-390957 (DB11719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK 79300 (100 mg, twice daily)
Trial: 1526015
Drug: UK 79300
RxNorm normalized name: UK-390957
DrugBank: UK-390957 (DB11719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK 79300 (25 mg)
Trial: 2868640
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg tablet of Ea-0643 (group-A)
Trial: 2868640
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg tablet of Ea-0643 (group-B)
Trial: 2868640
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet (group-C)
Trial: 27978537
Drug: Anti-rabies vaccine
RxNorm normalized name: rabies virus vaccine flury-lep strain Injection [RabAvert]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-rabies vaccine (control group)
Trial: 22976514
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy applied with output power of 100 mW in continuous mode with sweeping motion.
Trial: 16644631
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg muraglitazar
Trial: 10657761
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin (CAP) 0.05% liniment applied 3 times daily for 5 days